Product

Sapacitabine

Aliases

CYC682

1 clinical trial

1 indication

Indication

Acute Myeloid Leukemia

Clinical trial

A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes

Status: Completed, Estimated PCD: 2018-12-01